Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIVASTIGMINE vs ROFECOXIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIVASTIGMINE vs ROFECOXIB: Safety Overview

Metric RIVASTIGMINE ROFECOXIB
Total FAERS Reports 9,123 1,238
Deaths Reported 2,232 56
Death Rate 24.5% 4.5%
Hospitalizations 2,716 176
Average Patient Age 80.0 yrs 63.1 yrs
% Female Patients 59.5% 77.9%
FDA Approval Date Apr 21, 2000 Feb 25, 2000
Manufacturer Novartis Pharmaceuticals Corporation N/A
Route TRANSDERMAL N/A
Marketing Status Discontinued Discontinued